|Mapping the human genetic architecture of COVID-19|
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
|Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations|
H Hasegawa, H Yasuda, J Hamamoto, K Masuzawa, T Tani, S Nukaga, ...
Lung Cancer 127, 146-152, 2019
|Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations|
S Ikemura, H Yasuda, S Matsumoto, M Kamada, J Hamamoto, ...
Proceedings of the National Academy of Sciences 116 (20), 10025-10030, 2019
|IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung CancerIGF2–IGF1R Pathway Induces Resistance to Osimertinib|
T Manabe, H Yasuda, H Terai, H Kagiwada, J Hamamoto, T Ebisudani, ...
Molecular Cancer Research 18 (4), 549-559, 2020
|Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer|
K Kobayashi, K Naoki, T Manabe, K Masuzawa, H Hasegawa, H Yasuda, ...
OncoTargets and therapy 11, 3335, 2018
|Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm …|
K Kakimi, H Matsushita, K Masuzawa, T Karasaki, Y Kobayashi, ...
Journal for immunotherapy of cancer 8 (2), 2020
|Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan|
H Namkoong, R Edahiro, K Fukunaga, Y Shirai, K Sonehara, H Tanaka, ...
|SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer CellsSHOC2 Regulates NSCLC Response to EGFR–TKIs|
H Terai, J Hamamoto, K Emoto, T Masuda, T Manabe, S Kuronuma, ...
Molecular Cancer Research 19 (2), 317-328, 2021
|Monomer preference of EGFR tyrosine kinase inhibitors influences the synergistic efficacy of combination therapy with cetuximab|
A Oashi, H Yasuda, K Kobayashi, T Tani, J Hamamoto, K Masuzawa, ...
Molecular cancer therapeutics 18 (9), 1593-1601, 2019
|Upregulation of FGF9 in lung adenocarcinoma transdifferentiation to small cell lung cancer|
K Ishioka, H Yasuda, J Hamamoto, H Terai, K Emoto, TJ Kim, S Hirose, ...
Cancer research 81 (14), 3916-3929, 2021
|Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol|
K Nakagawara, H Namkoong, H Terai, K Masaki, T Tanosaki, ...
BMJ Open Respiratory Research 8 (1), e001015, 2021
|Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model|
K Kobayashi, H Terai, H Yasuda, J Hamamoto, Y Hayashi, O Takeuchi, ...
Biochemical and Biophysical Research Communications 534, 1-7, 2021
|Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer|
T Manabe, TG Bivona
Journal of Clinical Investigation 132 (4), e156891, 2022
|Establishment of patient-derived cancer cell lines to elucidate the resistant mechanism of tyrosine kinase inhibitors|
T Manabe, H Yasuda, H Terai, J Hamamoto, T Ebisudani, K Kobayashi, ...
Cancer Research 80 (16_Supplement), 2991-2991, 2020